Recent Articles

Found 63 Results
Page 1 of 7

Immuneering to Present at Oppenheimer’s Private Life Sciences Company Call Series

CAMBRIDGE, Mass., Aug. 11, 2020 (GLOBE NEWSWIRE) — Immuneering Corporation today announced the company’s participation in Oppenheimer’s Private Life Sciences Company Call Series taking place virtually August 17-19, 2020. Immuneering…


Immuneering Enters Collaboration with Astex Pharmaceuticals to Identify Novel Therapeutic Targets in Central Nervous System Disorder Using Disease Cancelling Technology

CAMBRIDGE, Mass., June 25, 2020 (GLOBE NEWSWIRE) — Immuneering Corporation today announced a collaboration between its neuroscience division, known as Alleo Labs, and Astex Pharmaceuticals (UK), a wholly owned subsidiary…


IMMUNEERING EXPANDS ONCOLOGY SCIENTIFIC ADVISORY BOARD WITH EXPERTS IN KEY CANCER SIGNALING PATHWAY

Oncology Scientific Advisory Board to support advancement of Immuneering’s drug programs modulating the RAS/MAPK signaling pathway in cancer   CAMBRIDGE, Mass. – March 25, 2020 – Immuneering Corporation today announced…


Immuneering CEO interviewed by Alex Keown of BioSpace, Inc

Published: Jan 28, 2020   By Alex Keown   In drug development, assets are often aimed at a specific disease target or pathway, similar to a bullet fired from a…


WSJ Pro: Venture Capital publishes article about Immuneering Corporation

IMMUNEERING RAISES $20 MILLION FOR NEW DRUG-DISCOVERY EFFORT Company formed in 2008 also provides services to pharmaceutical companies   By Brian Gormley   Venture capitalists are betting $20 million that…


IMMUNEERING RAISES $20 MILLION IN OVERSUBSCRIBED SERIES A FUNDING

FINANCING TO FUND IMMUNEERING’S PIPELINE INCLUDING PROGRAMS IN CANCER CACHEXIA, NEXT-GENERATION KRAS INHIBITION AND THE RAF-MEK PATHWAY, ALL DRIVEN BY ITS DISEASE CANCELLING TECHNOLOGY   CAMBRIDGE, Mass. – Jan. 22,…


The Bio Report Podcast

On this episode of The Bio Report podcast Immuneering co-founder and CEO Ben Zeskind discusses the company’s evolution from its roots in bioinformatics, movement into drug development, and the proprietary…


IMMUNEERING STRENGTHENS EXECUTIVE TEAM WITH APPOINTMENT OF HOWARD L. KAUFMAN, M.D., AS HEAD OF RESEARCH AND DEVELOPMENT

CANCER IMMUNOTHERAPY LEADER JOINS IMMUNEERING’S EXECUTIVE TEAM TO APPLY THE COMPANY’S DISEASE CANCELLING TECHNOLOGY TO IMMUNO-ONCOLOGY   CAMBRIDGE, Mass. – Jan. 9, 2020 – Immuneering Corporation today announced an addition…


IMMUNEERING APPOINTS SCOTT BARRETT, M.D., AS CHIEF MEDICAL OFFICER

INDUSTRY VETERAN JOINS EXECUTIVE TEAM AS IMMUNEERING ADVANCES RAPIDLY GROWING PIPELINE OF CANCER MEDICINES DRIVEN BY DISEASE CANCELLING TECHNOLOGY   CAMBRIDGE, Mass. – Dec. 19, 2019 – Immuneering Corporation today…


IMMUNEERING COMPLETES $17 MILLION SERIES A FINANCING

FUNDING TO ADVANCE RAPIDLY-GROWING PIPELINE OF CANCER MEDICINES DRIVEN BY DISEASE CANCELLING TECHNOLOGY AND EXPAND SERVICES BUSINESS   CAMBRIDGE, Mass. – Dec. 16, 2019 – Immuneering Corporation today announced the…


Page 1 of 7